BeiGene (BGNE) Competitors $194.26 +6.49 (+3.46%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends BGNE vs. BMRN, ALNY, GSK, TAK, BNTX, TEVA, VTRS, SMMT, MRNA, and GMABShould you be buying BeiGene stock or one of its competitors? The main competitors of BeiGene include BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), GSK (GSK), Takeda Pharmaceutical (TAK), BioNTech (BNTX), Teva Pharmaceutical Industries (TEVA), Viatris (VTRS), Summit Therapeutics (SMMT), Moderna (MRNA), and Genmab A/S (GMAB). These companies are all part of the "medical" sector. BeiGene vs. BioMarin Pharmaceutical Alnylam Pharmaceuticals GSK Takeda Pharmaceutical BioNTech Teva Pharmaceutical Industries Viatris Summit Therapeutics Moderna Genmab A/S BeiGene (NASDAQ:BGNE) and BioMarin Pharmaceutical (NASDAQ:BMRN) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, valuation, community ranking, risk, earnings, media sentiment, institutional ownership and dividends. Do analysts prefer BGNE or BMRN? BeiGene currently has a consensus target price of $247.07, suggesting a potential upside of 27.19%. BioMarin Pharmaceutical has a consensus target price of $94.20, suggesting a potential upside of 50.58%. Given BioMarin Pharmaceutical's stronger consensus rating and higher possible upside, analysts clearly believe BioMarin Pharmaceutical is more favorable than BeiGene.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BeiGene 0 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.71BioMarin Pharmaceutical 0 Sell rating(s) 7 Hold rating(s) 15 Buy rating(s) 1 Strong Buy rating(s) 2.74 Does the MarketBeat Community prefer BGNE or BMRN? BioMarin Pharmaceutical received 1019 more outperform votes than BeiGene when rated by MarketBeat users. Likewise, 74.52% of users gave BioMarin Pharmaceutical an outperform vote while only 69.20% of users gave BeiGene an outperform vote. CompanyUnderperformOutperformBeiGeneOutperform Votes54669.20% Underperform Votes24330.80% BioMarin PharmaceuticalOutperform Votes156574.52% Underperform Votes53525.48% Which has more risk & volatility, BGNE or BMRN? BeiGene has a beta of 0.63, meaning that its share price is 37% less volatile than the S&P 500. Comparatively, BioMarin Pharmaceutical has a beta of 0.31, meaning that its share price is 69% less volatile than the S&P 500. Is BGNE or BMRN more profitable? BioMarin Pharmaceutical has a net margin of 11.71% compared to BeiGene's net margin of -25.94%. BioMarin Pharmaceutical's return on equity of 8.53% beat BeiGene's return on equity.Company Net Margins Return on Equity Return on Assets BeiGene-25.94% -25.12% -14.95% BioMarin Pharmaceutical 11.71%8.53%6.40% Which has higher valuation and earnings, BGNE or BMRN? BioMarin Pharmaceutical has lower revenue, but higher earnings than BeiGene. BeiGene is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBeiGene$2.46B7.70-$881.71M-$8.24-23.58BioMarin Pharmaceutical$2.42B4.93$167.65M$1.6737.46 Does the media favor BGNE or BMRN? In the previous week, BeiGene had 11 more articles in the media than BioMarin Pharmaceutical. MarketBeat recorded 29 mentions for BeiGene and 18 mentions for BioMarin Pharmaceutical. BioMarin Pharmaceutical's average media sentiment score of 0.61 beat BeiGene's score of 0.31 indicating that BioMarin Pharmaceutical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BeiGene 10 Very Positive mention(s) 2 Positive mention(s) 9 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral BioMarin Pharmaceutical 9 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders believe in BGNE or BMRN? 48.6% of BeiGene shares are owned by institutional investors. Comparatively, 98.7% of BioMarin Pharmaceutical shares are owned by institutional investors. 7.4% of BeiGene shares are owned by company insiders. Comparatively, 1.9% of BioMarin Pharmaceutical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. SummaryBioMarin Pharmaceutical beats BeiGene on 14 of the 19 factors compared between the two stocks. Ad Wide Moat ResearchTrump said you could learn something from this manEarly Warning: A Deep Crack Is Forming In The US Economy Stocks are booming thanks to Trump’s landslide victory. Yet one former Trump advisor says the picture is less rosy than it seems. “I’ve found a deep crack forming in the foundations of the US economy,” he says. “And before too long, it could tear our country apart.” It’s critical you learn more today, BEFORE it impacts your money and your retirement. Here’s everything you need to know. Get BeiGene News Delivered to You Automatically Sign up to receive the latest news and ratings for BGNE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BGNE vs. The Competition Export to ExcelMetricBeiGenePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$18.92B$6.48B$5.05B$8.87BDividend YieldN/A8.12%4.97%4.06%P/E Ratio-23.585.5697.3414.18Price / Sales7.70348.141,218.4289.42Price / CashN/A22.1533.5132.79Price / Book5.247.885.805.12Net Income-$881.71M$153.61M$119.07M$225.99M7 Day Performance0.50%-2.00%-1.83%-1.32%1 Month Performance-11.67%-7.47%-3.64%0.60%1 Year Performance5.05%31.80%31.62%26.23% BeiGene Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BGNEBeiGene3.174 of 5 stars$194.26+3.5%$247.07+27.2%+3.4%$18.92B$2.46B-23.5810,600Analyst DowngradeGap UpBMRNBioMarin Pharmaceutical4.9885 of 5 stars$62.56+1.0%$94.20+50.6%-28.5%$11.92B$2.42B37.463,401ALNYAlnylam Pharmaceuticals4.3868 of 5 stars$248.79+6.2%$298.09+19.8%+50.5%$32.09B$1.83B-94.962,100Analyst ForecastGSKGSK4.4061 of 5 stars$33.36-0.3%$43.25+29.6%-5.0%$69.35B$37.71B21.6670,200Options VolumeTAKTakeda Pharmaceutical3.4202 of 5 stars$13.29-2.4%N/A-5.2%$43.34B$28.20B22.9149,281High Trading VolumeBNTXBioNTech3.4698 of 5 stars$102.14-4.0%$138.79+35.9%+3.3%$24.49B$3.04B-48.646,133Analyst ForecastAnalyst RevisionTEVATeva Pharmaceutical Industries2.6924 of 5 stars$17.03+1.2%$19.67+15.5%+80.0%$19.04B$15.85B0.0037,851VTRSViatris1.3448 of 5 stars$13.13+0.6%$13.33+1.5%+38.6%$15.58B$15.43B0.0038,000SMMTSummit Therapeutics1.8653 of 5 stars$18.62-6.9%$34.75+86.6%+835.7%$14.75B$700,000.000.00105Analyst ForecastMRNAModerna4.6286 of 5 stars$36.94-0.9%$84.00+127.4%-53.2%$14.35B$6.85B0.005,600Analyst UpgradeAnalyst RevisionGMABGenmab A/S4.3073 of 5 stars$20.45-0.2%$45.20+121.0%-37.0%$13.57B$2.39B19.852,204 Related Companies and Tools Related Companies BMRN Competitors ALNY Competitors GSK Competitors TAK Competitors BNTX Competitors TEVA Competitors VTRS Competitors SMMT Competitors MRNA Competitors GMAB Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:BGNE) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BeiGene, Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share BeiGene With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BGNE Stock Alerts